# Radiation-hormone and Docetaxel VS Radiation-hormone in Patients With High-Risk Localized Prostate Cancer

> **NCT03432780** · PHASE2 · UNKNOWN · sponsor: **Spanish Oncology Genito-Urinary Group** · enrollment: 134 (actual)

## Conditions studied

- Prostate Cancer Stage III
- Prostate Cancer Stage IV

## Interventions

- **DRUG:** Docetaxel
- **BIOLOGICAL:** Hormone and radiation therapy
- **RADIATION:** Radiation therapy

## Key facts

- **NCT ID:** NCT03432780
- **Lead sponsor:** Spanish Oncology Genito-Urinary Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-12-18
- **Primary completion:** 2023-11-14
- **Final completion:** 2023-11-14
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2021-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03432780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03432780, "Radiation-hormone and Docetaxel VS Radiation-hormone in Patients With High-Risk Localized Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03432780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*